MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

14.68 1.8

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.64

Max

14.8

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.2M -12M
Werknemers	37
EBITDA	-2.1M -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+121.76% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-206M 1.1B
Vorige openingsprijs	12.88
Vorige sluitingsprijs	14.68

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2026, 17:11 UTC

Belangrijke Marktbewegers

Belangrijke Nieuwsgebeurtenissen

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 apr 2026, 17:10 UTC

Belangrijke Nieuwsgebeurtenissen

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 apr 2026, 21:01 UTC

Belangrijke Nieuwsgebeurtenissen

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 apr 2026, 20:59 UTC

Acquisities, Fusies, Overnames

Starbucks and Boyu Capital Finalize China JV

2 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

2 apr 2026, 20:41 UTC

Winsten

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 20:32 UTC

Marktinformatie

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 apr 2026, 20:30 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 20:09 UTC

Marktinformatie

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 apr 2026, 20:01 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:46 UTC

Marktinformatie

Is Oil the New GameStop? -- Market Talk

2 apr 2026, 19:35 UTC

Marktinformatie

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 apr 2026, 19:29 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:24 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 apr 2026, 19:20 UTC

Marktinformatie

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 apr 2026, 19:01 UTC

Acquisities, Fusies, Overnames

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 apr 2026, 19:00 UTC

Acquisities, Fusies, Overnames

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 apr 2026, 18:24 UTC

Acquisities, Fusies, Overnames

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 apr 2026, 17:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 apr 2026, 17:32 UTC

Belangrijke Nieuwsgebeurtenissen

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 apr 2026, 17:26 UTC

Winsten

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 17:17 UTC

Marktinformatie

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 apr 2026, 17:09 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

121.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 32 USD 121.76%

Hoogste 42 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.